Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths. In
the last decade, the epidermal growth factor receptor (EGFR) signalling pathway has …

7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …

Background Erlotinib, docetaxel, and pemetrexed are approved for the second-line
treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large …

INTRODUCTION: Some patients with advanced NSCLC show prolonged disease
stabilization on treatment with an EGFR-tyrosine kinase inhibitor (TKI) such as erlotinib. It is …

Background: Erlotinib is proven to prolong survival, delay symptom progression and improve
quality of life for pts with advanced NSCLC (Shepherd et al. N Engl J Med 2005; 353: 123 …

Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …

Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …

19000 Background: Erlotinib significantly improved survival and quality of life while delaying
symptom progression compared with placebo in patients (pts) with relapsed NSCLC …